FrancophonIA/ELRC3.0 huggingface dataset:
English: For information about the administration of ZOSTAVAX and pneumococcal polysaccharide vaccine at the same time, talk to your doctor or health care provider.
Danish: Kontakt lægen eller sundhedspersonalet for information om samtidig administration af ZOSTAVAX og pneumokokpolysaccharidvaccinen.
English: Other medicines and ZOSTAVAX
Danish: Brug af anden medicin sammen med ZOSTAVAX
English: ZOSTAVAX is not indicated for treatment of zoster or PHN.
Danish: ZOSTAVAX er ikke indiceret til behandling af herpes zoster eller postherpetisk neuralgi (PHN).
English: The SPS study was a placebo-controlled, double-blind clinical trial in which 38,546 subjects were randomised to receive a single dose of either ZOSTAVAX or placebo and were followed for the development of zoster for a median of 3.1 years (range 31 days to 4.9 years).
Danish: Shingles Prevention Study (SPS) hos forsøgspersoner på 60 år og derover SPS-studiet var et placebokontrolleret, dobbeltblindet klinisk studie, hvor 38.546 forsøgspersoner blev randomiseret til at få en enkelt dosis af enten ZOSTAVAX eller placebo, og de blev kontrolleret for udvikling af zoster i mediant 3,1 år (spændvidde 31 dage til 4,9 år).
English: A concurrent placebo control was not available in the LTPS; data from prior placebo recipients were used to estimate vaccine efficacy.
Danish: Data fra tidligere placebo-vaccinerede blev brugt til at estimere vaccinens effekt.
English: VIAL OF POWDER
Danish: HÆTTEGLAS MED PULVER
English: Inject the entire content of the pre-filled syringe into the vial containing the powder.
Danish: Injicér hele indholdet af den forfyldte injektionssprøjte i hætteglasset med pulveret.
English: Sucrose, hydrolysed gelatin, sodium chloride, potassium dihydrogen phosphate, potassium chloride, monosodium L-glutamate monohydrate, disodium phosphate, sodium hydroxide (to adjust pH), and urea.
Danish: Saccharose, hydrolyseret gelatin, natriumchlorid, kaliumdihydrogenphosphat, kaliumchlorid, mononatrium-L-glutamatmonohydrat, dinatriumphosphat, natriumhydroxid (til justering af pH) og urea.
English: ZOSTAVAX significantly decreased the incidence of zoster compared to placebo (see Table 2).
Danish: ZOSTAVAX medførte en signifikant reduktion af incidensen af zoster sammenlignet med placebo (se Tabel 2).
English: Subjects with a history of herpes zoster (HZ) prior to vaccination In a double-blind, placebo-controlled, randomised clinical trial, ZOSTAVAX was administered to 100 subjects 50 years of age or older with a history of herpes zoster prior to vaccination to assess immunogenicity and safety (see section 4.8) of ZOSTAVAX.
Danish: Forsøgspersoner med herpes zoster (HZ) i anamnesen forud for vaccination I et dobbeltblindet, placebokontrolleret, randomiseret klinisk studie blev ZOSTAVAX givet til 100 forsøgspersoner i alderen fra 50 år og derover med herpes zoster i anamnesen forud for vaccination for at vurdere ZOSTAVAX' immunogenicitet og sikkerhed (se pkt.
English: The VZV specific immune responses to ZOSTAVAX at Week 4 post-vaccination were comparable whether administered by SC or IM route.
Danish: De VZV-specifikke immunresponser på ZOSTAVAX i Uge 4 efter vaccination svarede til hinanden uanset administrationsmåde (s.c. eller i.m.
English: One or 2 separate needles may be available in the packaging of the presentation containing the pre-filled syringe without attached needle.
Danish: Én eller to særskilte kanyler er muligvis tilgængelige i pakningen med forfyldt injektionssprøjte uden påmonteret kanyle.
English: Table 3: Efficacy of ZOSTAVAX on zoster incidence compared with placebo in the SPS in subjects 60 years of age and older*
Danish: Tabel 3: Effekten af ZOSTAVAX på incidensen af zoster sammenlignet med placebo i SPS hos forsøgspersoner på 60 og derover*
English: ZOSTAVAX significantly decreased the incidence of zoster compared with placebo (see Table 3).
Danish: ZOSTAVAX medførte en signifikant reduktion af incidensen af zoster sammenlignet med placebo (se Tabel 3).
English: The vaccine is a powder for suspension for injection contained in a single-dose vial, which should be reconstituted with the solvent provided with the vial of powder.
Danish: Vaccinen er et pulver, der skal opløses før injektion, opbevaret i et hætteglas, som indeholder en enkelt dosis.
English: Zostavax persistence of protection
Danish: Varighed af beskyttelsen med Zostavax
English: Before mixing with the solvent, the powder is a white to off-white compact crystalline plug.
Danish: Før det blandes med solvens, er pulveret en hvid/råhvid kompakt krystallinsk "prop".
English: Persistence of ZOSTAVAX efficacy was studied 4 to 7 years post-vaccination in the STPS, which included 7,320 subjects previously vaccinated with ZOSTAVAX and 6,950 subjects previously vaccinated with placebo in the SPS (mean age at enrollment was 73.3 years); and 7 to 10 years postvaccination in the Long-term Persistence Substudy (LTPS), which included 6,867 subjects previously vaccinated with ZOSTAVAX (mean age at enrollment into the LTPS was 74.5 years).
Danish: STPS omfattede 7320 forsøgspersoner i SPS, der tidligere var blevet vaccineret med ZOSTAVAX, og 6950 forsøgspersoner i SPS, der tidligere var blevet vaccineret med placebo (gennemsnitsalder ved indrulleringen var 73,3 år).
English: ZOSTAVAX is available in packs of 1 or 10.
Danish: Pakning med 1 eller 10 stk.
English: To reconstitute the vaccine, use the solvent provided.
Danish: Brug det vedlagte solvens til rekonstitution af vaccinen.
English: b. Tabulated summary of adverse events
Danish: b. Sammendrag af bivirkninger i tabelform
English: • if you are allergic (hypersensitive) to any of the components of this vaccine (including neomycin or any of the other ingredients listed in section 6)
Danish: • hvis De er allergisk (overfølsom) over for det aktive stof eller et af de øvrige indholdsstoffer
English: HIV-infected adults with conserved immune function In a clinical trial, ZOSTAVAX was administered to HIV-infected adults (18 years of age or older, CD4+ T cell count ≥ 200 cells/µL) (see section 5.1).
Danish: I et klinisk studie blev ZOSTAVAX givet til HIV-inficerede voksne (alder 18 år eller derover, CD4+ Tcelletal ≥ 200 celler/µl) (se pkt.
English: This leaflet was last revised in:
Danish: Denne indlægsseddel blev senest ændret
English: *These adverse reactions have been observed in clinical trials and through post-marketing surveillance; most of those observed in clinical trials were reported as mild in intensity.
Danish: *Disse bivirkninger er set i videnskabelige forsøg og ved opfølgning efter markedsføring.
English: After reconstitution, 1 dose (0.65 mL) contains: Varicella-zoster virus, Oka/Merck strain, (live, attenuated) ≥19,400 PFU
Danish: Efter rekonstitution indeholder 1 dosis (0,65 ml): Varicella-zoster-virus, Oka/Merck-stamme, (levende, attenueret) ≥19.400 PFU
English: Keep the vial in the outer carton to protect from light.
Danish: Må ikke fryses Opbevar hætteglasset i den ydre pakning for at beskytte mod lys.
English: Potassium dihydrogen phosphate Potassium chloride
Danish: Kaliumdihydrogenphosphat Kaliumchlorid
English: VIAL OF SOLVENT
Danish: HÆTTEGLAS MED SOLVENS
English: Inject all the solvent into the vial of lyophilised vaccine.
Danish: Injicér al solvens i hætteglasset med frysetørret vaccine.
English: • Immunosuppressive therapy (including high-dose corticosteroids) (see sections 4.4 and 4.8); however, ZOSTAVAX is not contraindicated for use in individuals who are receiving topical/inhaled corticosteroids or low-dose systemic corticosteroids or in patients who are receiving corticosteroids as replacement therapy, e.g., for adrenal insufficiency (see sections 4.8 and 5.1).
Danish: Dog er ZOSTAVAX ikke kontraindiceret til brug hos patienter, der behandles med topikale/inhalerede kortikosteroider eller systemiske lavdosiskortikosteroider eller hos patienter, som får kortikosteroider som substitutionsbehandling ved f.eks. binyrenyreinsufficiens (se pkt.
English: The safety and efficacy of ZOSTAVAX have not been established in adults who are known to be infected with HIV with or without evidence of immunosuppression (see section 4.3) however, a phase II safety and immunogenicity study in HIV-infected adults with conserved immune function (CD 4+T cell count ≥ 200 cells/µL) has been completed (see sections 4.8 and 5.1).
Danish: Der er dog blevet gennemført et fase II sikkerheds- og immunogenicitetsstudie med HIV-smittede voksne med bevaret immunfunktion (CD 4+T-celletal ≥ 200 celler/µl) (se pkt.
English: Powder and solvent for suspension for injection 1 vial (powder) + 1 vial (solvent) 10 vials (powder) + 10 vials (solvent)
Danish: Pulver og solvens til injektionsvæske, suspension 1 hætteglas (pulver) + 1 hætteglas (solvens) 10 hætteglas (pulver) + 10 hætteglas (solvens)
English: When reconstituted, ZOSTAVAX is a semi-hazy to translucent, off-white to pale yellow liquid.
Danish: Efter rekonstitution er ZOSTAVAX en let sløret til gennemskinnelig, råhvid til bleggul væske.
English: Transmission
Danish: Administration
English: EU/1/06/341/008 - pack of 1 EU/1/06/341/009 - pack of 10 EU/1/06/341/010 - pack of 20
Danish: EU/1/06/341/008 - pakning med 1 stk. EU/1/06/341/009 - pakning med 10 stk. EU/1/06/341/010 - pakning med 20 stk.
English: - If you have any further questions, ask your doctor or pharmacist.
Danish: Spørg lægen eller apotekspersonalet, hvis der er mere, De vil vide.
English: ZOSTAVAX with solvent for reconstitution supplied in a pre-filled syringe:
Danish: ZOSTAVAX med solvens til rekonstitution leveret i hætteglas Træk hele indholdet i hætteglasset med solvens op i en sprøjte.
English: ZOSTAVAX - Powder in vial and solvent in vial - Pack of 1, 10
Danish: ZOSTAVAX - Pulver i hætteglas og solvens i hætteglas - Pakning med 1, 10 stk.
English: Powder and solvent for suspension for injection in a pre-filled syringe 1 vial (powder) + 1 pre-filled syringe with needle (solvent) 10 vials (powder) + 10 pre-filled syringes with needle (solvent)
Danish: Pulver og solvens til injektionsvæske, suspension i forfyldt injektionssprøjte 1 hætteglas (pulver) + 1 forfyldt injektionssprøjte med kanyle (solvens) 10 hætteglas (pulver) + 10 forfyldte injektionssprøjter med kanyle (solvens)
English: Powder and solvent for suspension for injection in a pre-filled syringe 1 vial (powder) + 1 pre-filled syringe without needle (solvent) 10 vials (powder) + 10 pre-filled syringes without needle (solvent) 20 vials (powder) + 20 pre-filled syringes without needle (solvent)
Danish: 1 hætteglas (pulver) + 1 forfyldt injektionssprøjte uden kanyle (solvens) 10 hætteglas (pulver)+ 10 forfyldte injektionssprøjter uden kanyle (solvens) 20 hætteglas (pulver) + 20 forfyldte injektionssprøjter uden kanyle (solvens)
English: Powder in a vial (glass) with a stopper (butyl rubber) and flip off cap (aluminium) and solvent in a pre-filled syringe (glass) with plunger stopper (chlorobutyl rubber) and tip cap (styrene-butadiene rubber) without needle in pack size of 1, 10 or 20.
Danish: Pulver i hætteglas (glas) med prop (butylgummi) og låg (aluminium) og solvens i en forfyldt injektionssprøjte (glas) med stempelprop (chlorbutylgummi) og låg (styren-butadien gummi) uden kanyle i pakninger af 1, 10 eller 20 styk.
English: ZOSTAVAX elicited significantly higher VZV-specific immune responses at 6 weeks post-vaccination compared with placebo.
Danish: ZOSTAVAX udviste signifikant højere VZV-specifikke immunresponser 6 uger efter vaccination sammenlignet med placebo.
English: What ZOSTAVAX is and what it is used for What you need to know before you receive ZOSTAVAX How to use ZOSTAVAX
Danish: Oversigt over indlægssedlen: Virkning og anvendelse Det skal De vide, før De får ZOSTAVAX Sådan får De ZOSTAVAX Bivirkninger Opbevaring Pakningsstørrelser og yderligere oplysninger
English: Subjects who received ZOSTAVAX by SC (subcutaneous) or IM (intramuscular) route In an open-label, randomised, controlled clinical trial, ZOSTAVAX was administered either by SC route or by IM route to 353 subjects 50 years of age or older.
Danish: (intramuskulært) I et ikke-blindet, randomiseret, kontrolleret klinisk studie blev ZOSTAVAX enten givet s.c. eller i.m.
English: ZOSTAVAX - Powder in vial and solvent in pre-filled syringe without needle - Pack of 1, 10, 20
Danish: ZOSTAVAX - Pulver i hætteglas og solvens i forfyldte injektionssprøjter uden kanyle - Pakning med 1, 10 eller 20 stk.
English: EU/1/06/341/003 - pack of 1 EU/1/06/341/004 - pack of 10
Danish: EU/1/06/341/003 - pakning med 1 stk. EU/1/06/341/004 - pakning med 10 stk.
English: PRE-FILLED SYRINGE OF SOLVENT
Danish: FORFYLDT INJEKTIONSSPRØJTE MED SOLVENS
English: In subjects who developed zoster, ZOSTAVAX decreased the risk of subsequently developing PHN.
Danish: risikoen for efterfølgende at få PHN.
English: Withdraw the entire contents of the reconstituted vaccine using the same syringe.
Danish: Træk hele mængden fra hætteglasset med den rekonstituerede vaccine op med samme sprøjte.
English: ZOSTAVAX induced a significantly higher VZV-specific immune response at 4 weeks post-vaccination, compared with placebo.
Danish: ZOSTAVAX inducerede et signifikant højere VZV-specifikt immunrespons 4 uger efter vaccination sammenlignet med placebo.
English: EU/1/06/341/011 - pack of 1
Danish: EU/1/06/341/005 - pakning med 1 stk.
English: In any case, pregnancy should be avoided for one month following vaccination (see section 4.3).
Danish: Under alle omstændigheder bør graviditet undgås i 1 måned efter vaccination.
English: EU/1/06/341/012 - pack of 10 EU/1/06/341/013- pack of 20
Danish: EU/1/06/341/011 - pakning med 1 stk. EU/1/06/341/012 - pakning med 10 stk. EU/1/06/341/013 - pakning med 20 stk.
English: EU/1/06/341/001 - pack of 1 EU/1/06/341/002 - pack of 10
Danish: EU/1/06/341/001 - pakning med 1 stk. EU//1/06/341/002 - pakning med 10 stk.
English: Powder in a vial (glass) with a stopper (butyl rubber) and flip off cap (aluminium) and solvent in a pre-filled syringe (glass) with plunger stopper (chlorobutyl rubber) and tip cap (styrene-butadiene rubber) with one or two unattached needles in a pack size of 1, 10 or 20.
Danish: ZOSTAVAX med solvens til rekonstitution leveret i forfyldt injektionssprøjte Pulver i hætteglas (glas) med prop (butylgummi) og låg (aluminium) og solvens i en forfyldt injektionssprøjte (glas) med stempelprop (chlorbutylgummi) og låg (styren-butadien gummi) med én eller to særskilte kanyler i pakninger af 1, 10 eller 20 styk.
English: Mean BOI score
Danish: Middelværdi af BOIscore
English: ZOSTAVAX - Powder in vial and solvent in pre-filled syringe with 2 unattached needles - Pack of 1, 10, 20
Danish: ZOSTAVAX - Pulver i hætteglas og solvens i forfyldte injektionssprøjter med to separate kanylerPakning med 1, 10 eller 20 stk.
English: ZOSTAVAX was administered either subcutaneously (SC) or intramuscularly (IM) in subjects 50 years of age or older (see section 5.1).
Danish: ZOSTAVAX er blevet givet enten subkutant (s.c.) eller intramuskulært (i.m.)
English: ZOSTAVAX - Powder in vial and solvent in pre-filled syringe with one unattached needle - Pack of 1, 10, 20
Danish: ZOSTAVAX - Pulver i hætteglas og solvens i forfyldte injektionssprøjter med én separat kanylePakning med 1, 10 eller 20 stk.
English: Powder in a vial (glass) with a stopper (butyl rubber) and flip off cap (aluminium) and solvent in a pre-filled syringe (glass) with plunger stopper (chlorobutyl rubber) and needle shield (natural rubber), in a pack size of 1 or 10.
Danish: Pulver i hætteglas (glas) med prop (butylgummi) og låg (aluminium) og solvens i en forfyldt injektionssprøjte (glas) med stempelprop (chlorbutylgummi) og kanylebeskytter (naturgummi) i pakninger af 1 eller 10 styk.
English: Disease information on shingles:
Danish: Oplysninger om helvedesild:
English: ZOSTAVAX powder and solvent for suspension for injection shingles (herpes zoster) vaccine (live)
Danish: ZOSTAVAX Pulver og solvens til injektionsvæske, suspension Helvedesild (herpes zoster) vaccine (levende)
English: The general safety profiles of the SC and IM routes were otherwise comparable, but injection-site adverse reactions were significantly less frequent in the IM group (34%) compared with the SC group (64%).
Danish: administration svarede til hinanden, bortset fra at hyppigheden af bivirkninger på injektionsstedet var signifikant lavere i gruppen med i.m.
English: EU/1/06/341/005 - pack of 1 EU/1/06/341/006 - pack of 10 EU/1/06/341/007 - pack of 20
Danish: EU/1/06/341/006 - pakning med 10 stk. EU/1/06/341/007- pakning med 20 stk.
English: ZOSTAVAX powder and solvent for suspension for injection ZOSTAVAX powder and solvent for suspension for injection in a pre-filled syringe shingles (herpes zoster) vaccine (live)
Danish: ZOSTAVAX Pulver og solvens til injektionsvæske, suspension i forfyldt injektionssprøjte Helvedesild (herpes zoster) vaccine (levende)
English: Shingles Prevention Study (SPS) in Subjects 60 years of age and older:
Danish: †-score i SPS hos forsøgspersoner på 60 år og derover
English: The vaccine can be injected subcutaneously (SC) or intramuscularly (IM), preferably in the deltoid region (see sections 4.8 and 5.1).
Danish: Vaccinen kan injiceres subkutant (s.c.) eller intramuskulært (i.m.
English: Powder in a vial (glass) with a stopper (butyl rubber) and flip off cap (aluminium) and solvent in a vial (glass) with a stopper (chlorobutyl rubber) and flip off cap (aluminium) in a pack size of 1 or 10.
Danish: ZOSTAVAX med solvens til rekonstitution leveret i hætteglas Pulver i hætteglas (glas) med gummiprop (butylgummi) og låg (aluminium); solvens i hætteglas (glas) med gummiprop (chlorbutylgummi) og låg (aluminium) i pakninger af 1 eller 10 styk.
English: ZOSTAVAX Powder and solvent for suspension for injection in a pre-filled syringe shingles (herpes zoster) vaccine (live)
Danish: ZOSTAVAX pulver og solvens til injektionsvæske, suspension i forfyldt injektionssprøjte Helvedesild (herpes zoster) vaccine (levende)
English: ZOSTAVAX - Powder in vial and solvent in pre-filled syringe with attached needle Pack of 1,
Danish: ZOSTAVAX - Pulver i hætteglas og solvens i forfyldte injektionssprøjter med kanyler.
English: All patients were receiving standard treatment.
Danish: Alle patienter fik standardbehandling.
English: Treatment with Cablivi may continue for longer if necessary.
Danish: Behandlingen med Cablivi kan fortsætte i længere tid, hvis det er nødvendigt.
English: Patients also receive treatments to reduce the immune system's activity.
Danish: Patienterne får også behandling for at mindske immunsystemets aktivitet.
English: Other information about Cablivi
Danish: Andre oplysninger om Cablivi
English: As for all medicines, data on the use of Cablivi are continuously monitored.
Danish: Som for alle lægemidler bliver data vedrørende brugen af Cablivi løbende overvåget.
English: The most important side effect of treatment is bleeding but it is considered manageable.
Danish: Den vigtigste bivirkning ved behandlingen er blødning, men den er håndterbar.
English: The company is expected to provide results of a study on Cablivi's safety and effectiveness over a longer period.
Danish: Virksomheden forventes at fremlægge resultaterne af et studie af sikkerheden og virkningen af Cablivi over længere tid.
English: What measures are being taken to ensure the safe and effective use of Cablivi?
Danish: Hvilke foranstaltninger træffes der for at sikre risikofri og effektiv anvendelse af Cablivi?
English: For more information about using Cablivi, see the package leaflet or contact your doctor or pharmacist.
Danish: For mere information om brug af Cablivi, se indlægssedlen eller kontakt lægen eller apotekspersonalet.
English: Further information on Cablivi can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Danish: Yderligere information vedrørende Cablivi findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Patients or their carers may be able to inject Cablivi themselves after appropriate training.
Danish: Patienterne selv eller deres omsorgspersoner kan indgive Cablivi, når de er blevet behørigt oplært.
English: Further information on the orphan designation can be found here: ema.europa.eu/Find medicine/Human medicines/Rare disease designation
Danish: Yderligere oplysninger om udpegelsen til lægemiddel til sjældne sygdomme findes her: ema.europa.eu/Find medicine/Human medicines/Rare disease designation
English: The European Medicines Agency decided that Cablivi's benefits are greater than its risks and it can be authorised for use in the EU.
Danish: Det Europæiske Lægemiddelagentur konkluderede, at fordelene ved Cablivi opvejer risiciene, og at det kan godkendes til anvendelse i EU.
English: aTTP is rare, and Cablivi was designated an ‘orphan medicine' (a medicine used in rare diseases) on 30 April 2009.
Danish: aTTP er en sjælden sygdom, og Cablivi blev udpeget som "lægemiddel til sjældne sygdomme" den 30. april 2009.
English: Cablivi can only be obtained with a prescription.
Danish: Cablivi udleveres kun på recept.
English: The most common side effects with Cablivi (which may affect more than 1 in 10 people) are nosebleeds, headache and bleeding from gums.
Danish: De hyppigste bivirkninger ved Cablivi (som kan forekomme hos mere end 1 ud af 10 personer) er næseblod, hovedpine og blødning fra tandkødet.
English: Why is Cablivi authorised in the EU?
Danish: Hvorfor er Cablivi godkendt i EU?
English: Side effects reported with Cablivi are carefully evaluated and any necessary action taken to protect patients.
Danish: Bivirkninger rapporteret for Cablivi vurderes omhyggeligt, og der tages de nødvendige forholdsregler for at beskytte patienterne.
English: An overview of Cablivi and why it is authorised in the EU
Danish: En oversigt over Cablivi, og hvorfor det er godkendt i EU
English: Treatment should be started and supervised by doctors experienced in managing patients who have clotting disorders affecting small blood vessels.
Danish: Behandlingen bør iværksættes og overvåges af læger med erfaring i behandling af patienter, der har blodstørkningsforstyrrelser, som påvirker de små blodkar.
English: What is Cablivi and what is it used for?
Danish: Hvad er Cablivi, og hvad anvendes det til?
English: What are the risks associated with Cablivi?
Danish: Hvilke risici er der forbundet med Cablivi?
English: Cablivi contains the active substance caplacizumab.
Danish: Cablivi indeholder det aktive stof caplacizumab.
English: The company that markets Cablivi will provide materials, including a patient alert card, on the risk of serious bleeding and how the risk should be managed.
Danish: Den virksomhed, der markedsfører Cablivi, skal udarbejde informationsmaterialer, herunder et patientkort, vedrørende risikoen for alvorlig blødning og håndteringen af denne risiko.
English: During an episode of aTTP, blood clots form in small blood vessels and the patient has a low count of platelets (components that help the blood to clot).
Danish: Under en episode af aTTP dannes der blodpropper i små blodkar, og patienten har et lavt blodpladetal (en bestanddel i blodet, der hjælper det med at størkne).
English: Cablivi is used together with plasma exchange (in which certain antibodies are removed from the blood) and treatments to reduce the activity of the immune system (the body's defences).
Danish: Cablivi anvendes sammen med plasmaudskiftning (hvor visse antistoffer fjernes fra blodet) og behandlinger til at reducere aktiviteten af kroppens immunforsvar.
English: Caplacizumab, the active substance in Cablivi, is a nanobody (a small antibody) which has been designed to attach to von Willebrand factor in a way that stops it acting on platelets.
Danish: Caplacizumab, det aktive stof i Cablivi, er et nanostof (et lille antistof), der er designet til at binde til von Willebrand-faktor på en måde, så faktoren holder op med at virke på blodpladerne.
English: This reduces platelets sticking together and forming clots in blood vessels and, as a result, platelet levels in the blood rise because they are no longer taken up to form clots.
Danish: Dette reducerer blodpladernes evne til at klæbe og danne blodpropper i blodkarrene, og som følge deraf stiger niveauet af blodplader i blodet, da de ikke længere danner blodpropper.